Search Results

AIDS Funding for Federal Government Programs: FY1981-FY1999
This report provides a synopsis of the budget activity related to AIDS from the discovery of the disease in 1981 through FY1999. Funding for AIDS research, prevention and treatment programs within the Department of Health and Human Services (HHS) discretionary budget has increased from $200,000 in FY1981 to an estimated $3.85 billion in FY1999.
World Health Organization: A Fact Sheet
The World Health organization (WHO), established in 1948, is the United Nations system's authority on international public health issues. It assists governments in improving national health services and in establishing worldwide standards for foods, chemicals, and biological and pharmaceutical products. WHO concentrates on preventive rather than curative programs, including efforts to eradicate endemic and other widespread diseases, stabilize population growth, improve nutrition, sanitation, and maternal and child care. WHO is not an operational agency. It works through contracts with other agencies and private voluntary organizations.
Biotechnology, Indigenous Peoples, and Intellectual Property Rights
This report examines intellectual property right in pharmaceuticals in a particular context, namely, medicinal products and processes derived from the biodiversity resources of areas inhabited by indigenous peoples. This report discusses the international law regarding intellectual property rights in traditional knowledge and the American laws regarding traditional knowledge.
Gulf War Veterans' Illnesses
In 1990 and 1991, approximately 697,000 U.S. troops were deployed in the Persian Gulf during Operations Desert Shield and Desert Storm. The United States suffered relatively few casualties during the brief air and ground war against Iraq. Since returning home, however, many veterans have developed illnesses that appear to be related to their military service in the Gulf. Researchers caution that it may be impossible to identify the causes of these illnesses because of the absence of baseline data on the health of military personnel and the lack of reliable exposure data. This report provides concise answers to a series of questions concerning Gulf War veterans' illnesses, based on currently available scientific information.
Veterans and Smoking-Related Illnesses: Congress Enacts Limits to Compensation
With enactment of P.L. 105-178 (H.R. 2400), the Transportation Equity Act for the 21 Century (TEA-21), Congress limited authority of the Department of Veterans st Affairs (VA) to grant service-connected compensation to veterans who, after the enactment date, claim that their smoking-related illnesses are traceable to tobacco use that began during their military service. P.L. 105-178's prohibition on most smokingrelated VA claims is the resolution of an issue with potentially explosive federal costs. Subsequent technical amendments included in P.L. 105-205, the Internal Revenue Service reform legislation, removed the implication that smoking may have been misconduct, and made other minor clarifications.
Science, Technology, and Medicine: Issues Facing the 105th Congress, Second Session
Science, technology, and medicine are an integral part of many of the policy issues that might come before the Congress this second session. This report provides an overview of several of these issues and identifies CRS reports that treat them in more depth
Science, Technology, and Medicine: Issues Facing the 105th Congress, First Session
Science, technology, and medicine are an indisputable part of many of the policy issues that may come before the Congress this coming year. This report provides an overview of several of these issue and identifies CRS publications that treat them in more depth.
Science, Technology, and Medicine: Issues Facing the 106th Congress, First Session
Science, technology, and medicine is playing an integral part in many of the policy issues that are coming before this Congress. Legislative action in certain areas directly affects the progress of science, technology, and medicine (STM). And advances in those areas can significantly affect broader public policy issues. This issue brief provides an overview of several of those issues and identifies CRS reports that treat them in more depth.
Disease Funding and NIH Priority Setting
Research at the National Institutes of Health (NIH) has strong political support, but a heated debate rages over the allocation of NIH funds among various diseases. NIH contends that decisions are made based on scientific opportunity while critics of the NIH process charge that spending often follows current politics and political correctness.
Pfiesteria
Congress, federal agencies, and affected mid-Atlantic states are seeking to better understand Pftesteria piscicida, a recently identified species of dinoflagellate algae that appears to have harmful effects on both fish and human health, and to determine how best to mitigate its impacts. While individual states seek to address concerns, Congress and federal agencies are considering how best to assist state efforts. Issues of likely interest to Congress include water quality management, agriculture and its possible role in the problem, human health effects, and impacts on fisheries.
Cloning: Where Do We Go From Here?
News in February 1997 that scientists in Scotland had succeeded in cloning an adult sheep ignited a worldwide debate. Of concern are the ethical and social implications of the potential application of cloning to produce human beings. In response to concerns about the potential application of cloning to produce humans, actions were taken by the Administration and Congress.
Pfiesteria
Congress, federal agencies, and affected states are seeking to better understand Pfiesteriapiscicida (a recently identified species of dinoflagellate) and related species, whose blooms release toxins that can harm fish and possibly human health under certain conditions. Although menhaden, an industrial fish used primarily in fishmeal and oil production, is the dominant species observed to have been killed by these organisms, consumers have reduced their purchases of Chesapeake Bay seafood after extensive media coverage highlighted toxic events. Both the water and lipid-soluble toxins of Pfiesteria and related species have been blamed for adverse health effects in people who have come in contact with affected waters.
AIDS Funding for Federal Government Programs: FY1981-FY1999
This report provides a synopsis of the budget activity related to AIDS from the discovery of the disease in 1981 through FY1999. Funding for AIDS research, prevention and treatment programs within the Department of Health and Human Services (HHS) discretionary budget has increased from $200,000 in FY1981 to an estimated $3.85 billion in FY1999.
Cancer Research: Selected Federal Spending and Morbidity and Mortality Statistics
This report shows federal spending at the National Institutes of Health (NIH) for research on selected cancer sites.
Human Embryo Research
The FY1998 Labor-HHS-Education Appropriations Act, P.L. 105-78, enacted on November 13, 1997, prohibits the National Institutes of Health (NIH) from funding human embryo research in the fiscal year 1998. This ban applies to all federally supported investigations involving the creation of a human embryo or embryos for research purposes, and studies in which a human embryo is destroyed, discarded, or knowingly exposed to the risk of injury or death greater than that allowed for research on fetuses in utero as delineated in 45 CFR 46.208 (a)(2) and section 498(b) of the Public Health Service Act. The expression “human embryo or embryos” include any organism not protected under 45 CFR 46 (Protection of Human Subjects) that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes (egg and sperm, female and male sex cells, respectively) or human diploid cells. Current research involving human embryos, done in the private and international sectors pertain largely to the preimplantation embryo that results from in vitro fertilization.
Lead-Based Paint Poisoning Prevention: Federal Mandates for Local Government
The federal Lead-Based Paint Poisoning Prevention Act; as amended, established requirements for the detection and control of lead-based paint hazards in public and private housing. Only some local governments have implementation responsibilities, but all local governments are eligible for federal grants to establish poisoning prevention programs.
Prescription Drug User Fee Act of 1992: Effects on Bringing New Drugs to Market
No Description Available.
Tobacco Advertising: Whether the FDA's Restrictions Violate Freedom of Speech
No Description Available.
Tobacco Master Settlement Agreement (1998): Overview, Implementation by States, and Congressional Issues
On November 23, 1998, attorneys general representing 46 states, the District of Columbia, and the five U.S. territories signed an agreement with the major cigarette companies to settle all the state lawsuits seeking to recover the Medicaid costs of treating smokers. The Master Settlement Agreement, or MSA, contractually imposes some restrictions on tobacco advertising, marketing, and promotion and requires the manufacturers to make annual payments totaling about $206 billion through 2025. It follows earlier individual settlements with four states--Mississippi, Florida, Texas, and Minnesota--totaling more than $40 billion over the first 25 years. Cigarette price increases have passed on those settlement costs to smokers.
The Tobacco Settlement: Issues
Since 1994, 41 states and Puerto Rico have sued the tobacco industry to recover the medical costs of treating smokers. On June 20, 1997, a group of state attorneys general and industry lawyers announced that they had reached a settlement that would protect the tobacco companies from civil liability in return for annual industry payments of $365.5 billion over 25 years to reimburse states for their tobacco-related medical costs, and pay for tobacco control programs to reduce tobacco use among teenagers.
Compensating Farmers for the Tobacco Settlement
The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
The Proposed Tobacco Settlement: Effects on Prices, Smoking Behavior, and Income Distribution
No Description Available.
The Tobacco Settlement: An Overview
On June 20, a group of state attorneys general, plaintiffs' lawyers, public health advocates, and lawyers representing cigarette manufacturers announced an historic settlement that would restructure the tobacco industry and revolutionize the nation's tobacco control efforts. The proposed settlement is currently under congressional consideration, and would require legislation and the President's approval before taking effect
The Proposed Tobacco Settlement: Who Pays for the Health Costs of Smoking?
No Description Available.
Summary and Comparison of the Major Agricultural Provisions of the Tobacco Settlement Policy Proposals
No Description Available.
Tobacco Control: Enforcement and Effectiveness of Federal and State Youth Access Laws
This report reviews recent efforts to limit youth access to cigarettes through enforcement of federal and state laws prohibiting tobacco sales to minors. Under the federal Synar Amendment, states must conduct compliance checks and enforce their minimum age-of-sale laws or risk losing block grant funds
Tobacco Legislation in the 105th Congress: Side-by-Side Comparison of S. 1415, S. 1530, S. 1638, S. 1889, H.R. 3474, and H.R. 3868
No Description Available.
Tobacco Marketing and Advertising Restrictions in S. 1415, 105th Congress: First Amendment Issues
No Description Available.
Tobacco Issues: National Public Opinion
No Description Available.
Tobacco Marketing and Advertising Restrictions in S. 1648, 105th Congress: First Amendment Issues
No Description Available.
Tobacco Advertising: The Constitutionality of Limiting its Tax Deductibility
No Description Available.
Tobacco-Related Activities and Programs in the Federal Government: A Summary
No Description Available.
Tobacco-Related Programs and Activities of the U.S. Department of Agriculture: Operation and Cost
The U.S. Department of Agriculture (USDA) has long operated programs that directly assist farmers and others with the production and marketing of numerous crops, including tobacco. In most cases, the programs themselves are not controversial. Increasingly, however, where tobacco is involved, the use of federal funds is being called into question.
Tobacco Price Support: An Overview of the Program
Over 93% of U.S. tobacco production is flue-cured and burley (both being cigarette tobacco types). These crops are particularly important to the agriculture of North Carolina (where flue-cured is grown) and Kentucky (where burley is grown). Together, these two states produce 65% of the total U.S. tobacco crop. The federal tobacco price support program is designed to support and stabilize prices for farmers. It operates through a combination of mandatory marketing quotas and nonrecourse loans. Marketing quotas limit the amount of tobacco each farmer can sell, which indirectly raises market prices. The loan program establishes guaranteed minimum prices. The law requires that the loan program operate at no net cost to the federal government. Apart from year-to-year budget impacts, no-net-cost provisions of the law are intended to assure that all loan principal plus interest will be recovered
Back to Top of Screen